Results 1 to 10 of about 2,602 (175)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections [PDF]

Diagnostics, 2023
Hepatitis C virus (HCV) is a hepatotropic virus that affects millions of human lives worldwide. Direct-acting antiviral (DAA) regimens are the most effective HCV treatment option.
Mohammad Asrar Izhari
doaj   +2 more sources

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea [PDF]

Clinical and Molecular Hepatology, 2023
Background/Aims We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment in
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong   +12 more
doaj   +2 more sources

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats [PDF]

Pharmaceutics, 2023
Gadoxetate, a magnetic resonance imaging (MRI) contrast agent, is a substrate of organic-anion-transporting polypeptide 1B1 and multidrug resistance-associated protein 2.
Nicola Melillo, Daniel Scotcher, J. Gerry Kenna, Claudia Green, Catherine D. G. Hines, Iina Laitinen, Paul D. Hockings, Kayode Ogungbenro, Ebony R. Gunwhy, Steven Sourbron, John C. Waterton, Gunnar Schuetz, Aleksandra Galetin   +12 more
doaj   +2 more sources

Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals

The Korean Journal of Gastroenterology, 2021
The pegylated interferon plus ribavirin combination therapy has been used as the primary treatment for chronic hepatitis C (CHC) but fails to produce a sustained viral response (SVR) in many patients.
Dong Hoon Lee, Soo Hyung Ryu, Hee jun Myung, Yun Jae Shin, Si Hyeong Lee, Tae Young Park, Jeong Seop Moon   +6 more
doaj   +1 more source

Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy. [PDF]

PLoS ONE, 2018
AIMS:Liver injury can occur during antiviral therapies with direct-acting antivirals (DAAs), potentially necessitating discontinuation of the therapies, with consequent worsening of the sustained viral response (SVR) rates, in patients with hepatitis C ...
Yoshihito Uchida, Kayoko Naiki, Jun-Ichi Kouyama, Kayoko Sugawara, Masamitsu Nakao, Daisuke Motoya, Mie Inao, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida   +10 more
doaj   +1 more source

Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection

JGH Open, 2022
Background and Aim This study aimed to evaluate the long‐term clinical course of patients achieving a sustained virologic response (SVR) with daclatasvir plus asunaprevir (DCV/ASV) therapy.
Hideki Fujii, Hiroyuki Kimura, Chitomi Hasebe, Takehiro Akahane, Takashi Satou, Atsunori Kusakabe, Yuji Kojima, Masahiko Kondo, Hiroyuki Marusawa, Haruhiko Kobashi, Keiji Tsuji, Chikara Ogawa, Yasushi Uchida, Kouji Joko, Akeri Mitsuda, Masayuki Kurosaki, Namiki Izumi   +16 more
doaj   +1 more source

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak   +14 more
doaj   +1 more source

Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus

Frontiers in Microbiology, 2017
Type I Interferon-mediated innate immunity against Flaviviridae, such as Hepatitis C virus (HCV) and Dengue virus (DENV), involves TLR3, RIG-I-like receptor (RLR) and JAK-STAT signal pathways.
Wei-Lun Tsai, Wei-Lun Tsai, Tsung-Hsien Chang, Tsung-Hsien Chang, Jin-Shiung Cheng, Jin-Shiung Cheng, Chih-Wen Shu, Kwok-Hung Lai, Kwok-Hung Lai, Hoi-Hung Chan, Hoi-Hung Chan, Chun-Ching Wu, Jing-Mei Wu, Ping-I Hsu, Ping-I Hsu, Raymond T. Chung   +15 more
doaj   +1 more source

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Gut and Liver, 2018
Background/AimsThe treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection.
Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park   +10 more
doaj   +1 more source

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced

Gut and Liver, 2017
Background/AimsChronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia.Methods : Patients (n=30) were enrolled between September 2015 and April 2016.
Hyun Woong Lee, Ki Young Yoo, Joung Won Won, Hyung Joon Kim   +3 more
doaj   +1 more source